Case report a case of durvalumab induced aplastic anemia after chemoradiotherapy for NSCLC

Spigel, 2022, Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, J. Clin. Oncol., 40, 1301, 10.1200/JCO.21.01308 Stewart, 2015, Identification and characterization of MEDI4736, an antagonistic anti–PD-L1 monoclonal antibody, Cancer Immunol. Res. Am. Assoc. Cancer Res., 3, 1052, 10.1158/2326-6066.CIR-14-0191 Bruni, 2021, Multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable Stage III non-small cell lung cancer, Front. Oncol., 11 Rouvinov, 2019, Nivolumab induced lethal aplastic anemia in a patient with metastatic melanoma, Case Rep. Oncol., 12, 29, 10.1159/000495980 Davis, 2019, Hematologic complications of immune checkpoint inhibitors, Oncologist, 24, 584, 10.1634/theoncologist.2018-0574 Delanoy, 2019, Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study, Lancet Haematol., 6, e48, 10.1016/S2352-3026(18)30175-3 Wenhan, 2020, Immune suppression therapy in aplastic anemia secondary to atezolizumab in a patient with Stage IV non-small cell lung cancer, Int. J. Med. Rev. Case Rep., 4, 18 Young, 2018, Aplastic anemia, N. Engl. J. Med., 379, 1643, 10.1056/NEJMra1413485 Hosokawa, 2016, Memory stem T cells in autoimmune disease: high frequency of circulating CD8+ memory stem cells in acquired aplastic anemia, J. Immunol., 196, 1568, 10.4049/jimmunol.1501739 Zhao, 2017, High programmed death 1 expression on T cells in aplastic anemia, Immunol. Lett., 183, 44, 10.1016/j.imlet.2017.01.016